Additional data proving its α-tubulin acetylation property in PD models exclusively, along with its subsequent impact on motor protein binding and mitochondrial motility, can be fruitful for recognizing SIRT2 inhibitors as a therapeutic line of class for preventing PD progression. The gene discussed is IMMT; the disease is Parkinson disease.